Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, JAN. 08, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC . (MONTE ROSA) (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 11,125,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $24.00 PER SHARE AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 1,375,000 SHARES OF COMMON STOCK AT A PUBLIC OFFERING PRICE OF $23.9999 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

MONTE ROSA THERAPEUTICS ANNOUNCES PRICING OF $300 MILLION UNDERWRITTEN PUBLIC OFFERING

BOSTON, JAN. 07, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (MONTE ROSA) (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $200.0 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK. ALL OF THE SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK IN THE PROPOSED OFFERING ARE TO BE SOLD BY MONTE ROSA.

MONTE ROSA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

IN SUBJECTS WITH ELEVATED CARDIOVASCULAR DISEASE (CVD) RISK, MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER IN DEVELOPMENT FOR THE TREATMENT OF NLRP3/IL-1/IL-6 DRIVEN INFLAMMATORY DISEASES, DEMONSTRATED RAPID AND DURABLE REDUCTIONS IN SYSTEMIC INFLAMMATION AFTER FOUR WEEKS OF MRT-8102 TREATMENT, C-REACTIVE PROTEIN (CRP) LEVELS WERE REDUCED BY 85%, AND 94% OF STUDY PARTICIPANTS ACHIEVED CRP VALUES BELOW 2 MG/L, A THRESHOLD ASSOCIATED WITH REDUCED CARDIOVASCULAR DISEASE (CVD) RISK SINGLE ASCENDING DOSE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) COHORTS DEMONSTRATED DEEP AND SUSTAINED NEK7 DEGRADATION AT DOSES FROM 5 MG TO 400 MG FAVORABLE SAFETY PROFILE OBSERVED WITH MILD TO MODERATE ADVERSE EVENTS (AES) AND NO EVIDENCE OF INCREASED INFECTION RISK ONGOING GFORCE-1 STUDY OF MRT-8102 IN SUBJECTS WITH ELEVATED CVD RISK EXPANDED TO MULTIPLE DOSE LEVELS TO ACCELERATE DEVELOPMENT IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD); ANTICIPATED READOUT IN H2 2026 PLAN TO INITIATE PHASE 2 ASCVD STUDY IN 2026; ADDITIONAL INDICATIONS BEING EVALUATED CONFERENCE CALL AND WEBCAST PLANNED FOR TODAY AT 8 A.M. ET BOSTON, JAN. 07, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED POSITIVE INTERIM DATA FROM AN ONGOING PHASE 1 CLINICAL STUDY EVALUATING MRT-8102, A NEK7-DIRECTED MGD BEING DEVELOPED FOR THE TREATMENT OF INFLAMMATORY CONDITIONS DRIVEN BY THE NLRP3 INFLAMMASOME, IL-1, AND IL-6.

MONTE ROSA THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 1 DATA OF MRT-8102 DEMONSTRATING PROFOUND CRP REDUCTIONS IN ELEVATED CVD-RISK SUBJECTS

BOSTON, JAN. 06, 2026 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT MANAGEMENT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST ON WEDNESDAY, JANUARY 7, AT 8:00 A.M. ET. THE WEBCAST PRESENTATION WILL HIGHLIGHT INTERIM CLINICAL RESULTS FROM THE ONGOING PHASE 1 STUDY OF THE NEK7-DIRECTED MGD MRT-8102, INCLUDING INTERIM DATA FROM THE ONGOING PART 3 CRP PROOF-OF-CONCEPT COHORT IN SUBJECTS WITH ELEVATED CARDIOVASCULAR DISEASE RISK.

MONTE ROSA THERAPEUTICS TO PRESENT INTERIM MRT-8102 PHASE 1 STUDY RESULTS

IN MCRPC PATIENTS WITH ANDROGEN RECEPTOR (AR) MUTATIONS, TREATMENT WITH MRT-2359 IN COMBINATION WITH ENZALUTAMIDE LED TO A 100% PSA RESPONSE RATE (4 OF 4 PATIENTS) AND A 100% DISEASE CONTROL RATE, INCLUDING 2 PATIENTS WITH RECIST RESPONSES AND 2 WITH STABLE DISEASE COMBINATION OF MRT-2359 AND ENZALUTAMIDE WAS GENERALLY WELL-TOLERATED WITH PRIMARILY GRADE 1-2 ADVERSE EVENTS COMPANY PLANS TO INITIATE A NEW, SIGNAL-CONFIRMING PHASE 2 STUDY OF MRT-2359 TARGETING AR MUTANT AND AR SIGNALING-DEPENDENT PATIENTS IN 2026 UPDATED MRT-2359 DATA EXPECTED TO BE PRESENTED AT ASCO GENITOURINARY CANCERS SYMPOSIUM IN FEBRUARY 2026 CONFERENCE CALL AND WEBCAST PLANNED FOR TODAY AT 8 A.M. ET BOSTON, DEC. 16, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED POSITIVE INTERIM DATA FROM AN ONGOING PHASE 1/2 CLINICAL STUDY EVALUATING MRT-2359 IN COMBINATION WITH ENZALUTAMIDE IN HEAVILY PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).

MONTE ROSA THERAPEUTICS ANNOUNCES COMPELLING CLINICAL ACTIVITY OF MRT-2359 IN COMBINATION WITH ENZALUTAMIDE IN HEAVILY PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH ANDROGEN RECEPTOR MUTATIONS

BOSTON, DEC. 15, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT MANAGEMENT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST ONTUESDAY, DECEMBER 16, 2025, AT8:00 A.M. ET. THE WEBCAST PRESENTATION WILL HIGHLIGHT INTERIM CLINICAL RESULTS FROM THE ONGOING PHASE 1/2 STUDY OF THE GSPT1-DIRECTED MGD MRT-2359 IN HEAVILY PRETREATED, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS.

MONTE ROSA THERAPEUTICS TO PRESENT UPDATED MRT-2359 PHASE 1/2 STUDY RESULTS

AGENCY WILL PARTNER WITH GORILLA GLUE ON CREATIVE CAMPAIGNS THAT BUILD ON THE BRAND'S TOUGHNESS EQUITY MINNEAPOLIS , NOV. 19, 2025 /PRNEWSWIRE/ -- BETTY, A QUAD AGENCY, TODAY ANNOUNCED IT HAS BEEN NAMED THE CREATIVE AGENCY FOR GORILLA GLUE, A LEADER IN TOUGH ADHESIVES. GORILLA GLUE JOINS THE GROWING ROSTER OF BRANDS TURNING TO BETTY FOR STRATEGIC, IMAGINATIVE CREATIVE THAT DRIVES BUSINESS GROWTH.

BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE

DATA SUPPORT NEK7 AS A POTENTIAL NOVEL AND DIFFERENTIATED THERAPEUTIC APPROACH TO MODULATE THE NLRP3 INFLAMMASOME IN MULTIPLE CARDIOVASCULAR AND CARDIOMETABOLIC DISEASES, INCLUDING PERICARDITIS AND ATHEROSCLEROSIS INITIAL DATA FROM A PHASE 1 STUDY OF MRT-8102 IN HEALTHY VOLUNTEERS AND ELEVATED CVD-RISK SUBJECTS ON TRACK FOR FIRST HALF OF 2026 POSTER PRESENTATION ON NOVEMBER 8 AT 10:30 A.M. CST BOSTON, NOV. 08, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC.(NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THE COMPANY WILL PRESENT PRECLINICAL DATA ON THE POTENTIAL OF MRT-8102, A FIRST-IN-CLASS, NEK7-DIRECTED MGD FOR INFLAMMATORY DISEASES DRIVEN BY THE NLRP3 INFLAMMASOME, AT THE AMERICAN HEART ASSOCIATION'S SCIENTIFIC SESSIONS 2025, HELD NOVEMBER 7-10 IN NEW ORLEANS, LA.

MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA AT AHA SCIENTIFIC SESSIONS 2025 ON THE POTENTIAL OF MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER, TO TREAT CARDIOVASCULAR AND CARDIOMETABOLIC DISEASES

SECOND AGREEMENT SIGNED WITH NOVARTIS TO DEVELOP NOVEL DEGRADERS FOR IMMUNE-MEDIATED DISEASES, PROVIDING UPFRONT PAYMENT OF $120 MILLION PLUS OPTION MAINTENANCE PAYMENTS, AND ELIGIBILITY FOR OPTION EXERCISE PAYMENTS, MILESTONES, AND TIERED ROYALTIES PHASE 1 STUDY OF NEK7-DIRECTED MGD MRT-8102 UNDERWAY, INVESTIGATING A POTENTIAL NOVEL APPROACH TO TREAT INFLAMMATORY DISEASES DRIVEN BY THE NLRP3 INFLAMMASOME; INITIAL READOUT INCLUDING DATA FROM HIGH-CVD RISK COHORT ON TRACK FOR H1 2026 VAV1-DIRECTED MGD MRT-6160 ADVANCING TOWARD ANTICIPATED INITIATION OF MULTIPLE PHASE 2 STUDIES IN IMMUNE-MEDIATED DISEASES PHASE 1/2 STUDY OF GSPT1-DIRECTED MGD MRT-2359 ADVANCING IN HEAVILY PRETREATED, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS; ADDITIONAL RESULTS EXPECTED BY YEAR-END STRONG CASH POSITION EXPECTED TO FUND OPERATIONS THROUGH 2028, ENABLING MULTIPLE ANTICIPATED PROOF-OF-CONCEPT CLINICAL READOUTS ACROSS THE PORTFOLIO BOSTON, NOV. 06, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY REPORTED BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. WITH THREE PROGRAMS IN CLINICAL DEVELOPMENT AND A HIGHLY PRODUCTIVE DRUG DISCOVERY ENGINE CREATING ADDITIONAL FUTURE OPPORTUNITIES, WE ARE BUILDING A LEADING PROTEIN DEGRADATION COMPANY INNOVATING IN THE MOLECULAR GLUE DEGRADER SPACE, SAID MARKUS WARMUTH, M.D.

MONTE ROSA THERAPEUTICS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATES

BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT MARKUS WARMUTH, M.D., CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN FIRESIDE CHATS AT THE FOLLOWING INVESTOR CONFERENCES: GUGGENHEIM 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE (BOSTON, MA)  NOVEMBER 10, 2025, AT 11:30 A.M.

MONTE ROSA THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

MRT-6160 INHIBITED DISEASE PATHOLOGY, INCLUDING PROTEINURIA, LYMPHADENOPATHY, SKIN LESION FORMATION, AUTOANTIBODY PRODUCTION, AND ORGANOMEGALY, IN A SPONTANEOUS AUTOIMMUNE DISEASE MOUSE MODEL DATA SUPPORT THE POTENTIAL OF MRT-6160 TO ADDRESS MULTIPLE RHEUMATIC AUTOIMMUNE AND INFLAMMATORY DISEASES, INCLUDING SJGREN'S DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS, AND RHEUMATOID ARTHRITIS POSTER PRESENTATION ON OCTOBER 26TH AT 10:30 AM CDT BOSTON, OCT. 24, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC.(NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THE COMPANY WILL PRESENT PRECLINICAL DATA ON THE POTENTIAL OF MRT-6160, A RATIONALLY DESIGNED MOLECULAR GLUE DEGRADER (MGD) THAT SELECTIVELY DEGRADES VAV1, TO TREAT MULTIPLE AUTOIMMUNE AND INFLAMMATORY DISEASES, AT ACR CONVERGENCE 2025, HELD OCTOBER 24-29 IN CHICAGO, IL. IN A PRECLINICAL AUTOIMMUNE DISEASE MODEL CHARACTERIZED BY CHRONIC INFLAMMATION, AUTOANTIBODY PRODUCTION, AND MULTI-ORGAN INVOLVEMENT, ADMINISTRATION OF MRT-6160 RESULTED IN BROAD ACTIVITY ACROSS AN ARRAY OF DISEASE MARKERS, INCLUDING ATTENUATED AUTOANTIBODY LEVELS AND REDUCED SKIN AND KIDNEY PATHOLOGY, SAID SHARON TOWNSON, PH.D.

MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA AT ACR CONVERGENCE 2025 ON THE POTENTIAL OF MRT-6160, A VAV1-DIRECTED MOLECULAR GLUE DEGRADER, TO TREAT IMMUNE-MEDIATED DISEASES

NOVARTIS RECEIVES AN EXCLUSIVE LICENSE TO AN UNDISCLOSED DISCOVERY TARGET NOVARTIS ALSO RECEIVES OPTIONS TO LICENSE TWO PROGRAMS FROM MONTE ROSA'S GROWING PRECLINICAL IMMUNOLOGY PORTFOLIO MONTE ROSA TO RECEIVE AN UPFRONT PAYMENT OF $120 MILLION, PLUS OPTION MAINTENANCE PAYMENTS, AND IS ELIGIBLE FOR OPTION EXERCISE PAYMENTS AND DEVELOPMENT, REGULATORY, AND SALES MILESTONES, AS WELL AS TIERED ROYALTIES ON GLOBAL NET SALES EXTENDED CASH RUNWAY ENABLES MONTE ROSA TO ACCELERATE PRECLINICAL AND CLINICAL-STAGE IMMUNOLOGY & INFLAMMATION (I&I) PIPELINE BOSTON, MASS., SEPT. 15, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED AN AGREEMENT TO COLLABORATE WITH NOVARTIS TO DEVELOP NOVEL DEGRADERS FOR IMMUNE-MEDIATED DISEASES.

MONTE ROSA THERAPEUTICS ANNOUNCES COLLABORATION WITH NOVARTIS FOR DEGRADERS TO TREAT IMMUNE-MEDIATED DISEASES

BOSTON, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC. (NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE (NEW YORK, NY)  SEPTEMBER 8, 2025.

Monte Rosa Therapeutics, Inc.

GLUE

Price

Financial Reports

No items found.

Press Releases

Monte Rosa Therapeutics, Inc.

GLUE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GLUE